Page last updated: 2024-12-10
1-salicylate glucuronide
Description
## 1-Salicylate Glucuronide: What it is and why it's important
**1-Salicylate glucuronide** is a **metabolite** of **salicylic acid**, the active ingredient in aspirin. It's formed in the liver via a process called **glucuronidation**, where a molecule of glucuronic acid is attached to salicylate.
**Here's why it's important for research:**
* **Pharmacokinetic studies:** Understanding the metabolism of salicylate is crucial for **determining the pharmacokinetic properties** of aspirin, such as its absorption, distribution, metabolism, and excretion. This knowledge is essential for optimizing drug dosage and minimizing side effects.
* **Toxicity studies:** Salicylate glucuronide formation is important for **understanding the toxicity of salicylate**. Since glucuronidation helps to detoxify salicylate, measuring levels of this metabolite can indicate the efficiency of the detoxification process and the potential for toxicity.
* **Disease research:** 1-Salicylate glucuronide levels can also be studied in the context of various diseases. For example, **reduced glucuronidation** has been linked to **liver disease** and **certain genetic disorders**, making it a potential biomarker for these conditions.
* **Clinical applications:** Measuring salicylate glucuronide levels in patients can help clinicians assess **the effectiveness of aspirin therapy** and monitor for potential toxicity. This is especially important for patients taking high doses of aspirin or those with compromised liver function.
* **Drug interactions:** Certain drugs can inhibit or induce glucuronidation, affecting the levels of 1-salicylate glucuronide and potentially impacting the efficacy and safety of aspirin therapy.
**Overall, 1-salicylate glucuronide is a valuable tool for researchers and clinicians seeking to understand the metabolism, toxicity, and clinical implications of aspirin. Its importance stems from its role in the detoxification of salicylate and its potential as a biomarker for various conditions.**
1-salicylate glucuronide: urinary metabolite of salicylic acid; RN given refers to (beta-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-salicylate glucuronide : A beta-D-glucosiduronic acid that is the glucuronide conjugate of salicyclic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 3084023 |
| CHEMBL ID | 1371375 |
| CHEBI ID | 73961 |
| SCHEMBL ID | 21594800 |
| MeSH ID | M0142920 |
Synonyms (27)
| Synonym |
|---|
| beta-d-glucopyranosiduronic acid, 2-carboxyphenyl |
| salicylphenolic glucuronide |
| salicyl phenolic glucuronide |
| 7695-70-7 |
| 1-salicylate glucuronide |
| phenolic sa glucuronide |
| salicylic glucuronide |
| salicylic acid glucuronide |
| (2s,3s,4s,5r,6s)-6-(2-carboxyphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid |
| 2-carboxyphenyl beta-d-glucopyranosiduronic acid |
| CHEBI:73961 , |
| salicylic acid beta-d-o-glucuronide |
| DTXSID20227737 |
| W-203760 |
| salicylic acid phenolic d-glucuronide |
| JSCWDKKMLIQCMR-CDHFTJPESA-N |
| .beta-d-glucopyranosiduronic acid, 2-carboxyphenyl |
| salicylic acid .beta.-d-o-glucuronide |
| salicyl glucuronide |
| CHEMBL1371375 |
| 1-salicylic acid glucuronide |
| SCHEMBL21594800 |
| Q27144282 |
| salicylic acid ?-d-o-glucuronide |
| salicylic acid beta -d-o-glucuronide |
| PD150553 |
| AKOS040755856 |
Research Excerpts
Pharmacokinetics
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| "The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic acid (SA) metabolites were studied at three aspirin dosage regimens in eight patients with rheumatoid arthritis." | ( Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.
Bochner, F; Cleland, LG; Graham, GG; Imhoff, DM; Polverino, A; Rolan, PE; Tregenza, RA, 1987) | 0.27 |
| " Effects of ASA dosage on the metabolic profile have not been fully understood." | ( Quantitative determination of five metabolites of aspirin by UHPLC-MS/MS coupled with enzymatic reaction and its application to evaluate the effects of aspirin dosage on the metabolic profile.
Duan, JA; Guo, JM; Li, JP; Liu, Y; Shang, EX; Tang, ZS; Zhao, BC; Zhao, J; Zhu, ZH, 2017) | 0.46 |
Roles (1)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
| Class | Description |
|---|
| beta-D-glucosiduronic acid | A glucosiduronic acid resulting from the formal condensation of any substance with beta-D-glucuronic acid to form a glycosidic bond. |
| benzoic acids | Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.23 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.18 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |